Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis

Thorax

Volumn 55, Issue 3, 2000, Pages 205-209

  Kharitonov, Sergei A ^a   Corradi, Massimo ^a   van Rensen, Liesbeth ^a   Geddes, Duncan M ^a   Hodson, Margaret E ^a   Barnes, Peter J ^a   Montuschi, Paolo ^b   Ciabattoni, Giovanni ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

8 Isoprostane; Cystic fibrosis; Oxidative stress

Indexed keywords

ARACHIDONIC ACID; BIOLOGICAL MARKER; CARBON MONOXIDE; FREE RADICAL; ISOPROSTANE; NITRIC OXIDE;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ASTHMA; BREATH ANALYSIS; BRONCHUS SECRETION; CHEMOLUMINESCENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME IMMUNOASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PEROXIDATION; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; BREATH TESTS; CARBON MONOXIDE; CYSTIC FIBROSIS; DINOPROST; F2-ISOPROSTANES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; NITRIC OXIDE; OXIDATIVE STRESS; VITAL CAPACITY;

EID: 0034059997     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.55.3.205     Document Type: Article

References (30)

1. 1 Brown RK, Wyatt H, Price JF, et al. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur Respir J 1996;9:334-9.
2. 2 McGrath LT, Mallon P, Dowey L, et al. Oxidative stress during acute respiratory exacerbations in cystic fibrosis. Thorax 1999;54:518-23.
3. 3 Holsclaw DS. Cystic fibrosis and pulmonary involvement from multiple perspectives. Semin Respir Infect 1993;7:141-50.
4. 4 Babior BM. The respiratory burst oxidase. Trends Biomed Sci 1987;12:241-3.
5. 5 Brown RK, Kelly FJ. Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatr Res 1994;36:487-93.
6. 6 Hull J, Vervaart P, Grimwood K, et al. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 1997;52:557-60.
7. 7 Witko-Sarasat V, Delacourt C, Rabier D, et al. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum. Am J Respir Crit Care Med 1995;152:1910-16.
8. 8 Moore K, Roberts LJ. Measurement of lipid peroxidation. Free Radic Res 1998;28:659-71.
9. 9 Morrow JD, Awad JA, Boss HJ, et al. Non-cyclooxygenase derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992;89:10721-5.
10. 10 Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free-radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-7.
11. 2α excretion in man. J Pharmacol Exp Ther 1995;275:94-100.
12. 12 Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. N Engl J Med 1995;332:1198-203.
13. 13 Stein CM, Tanner SB, Awad JA, et al. Evidence for a free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996;39:1146-50.
14. 14 Montuschi P, Ciabattoni G, Paredi P, et al. 8-isoprostane as a biomarker of oxidative stress in interstitial lung disease. Am J Respir Crit Care Med 1998;158:1524-7.
15. 15 Praticò P, Basili S, Vieri M, et al. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2α-III, an index of oxidant stress. Am J Respir Crit Care Med 1998;158:1709-14.
16. 16 Carpenter CT, Price PV, Christman BW. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury and ARDS. Crest 1998;114:1653-9.
17. 17 Montuschi P, Corradi M, Ciabattoni G, et al. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthmatics patients. Am J Respir Crit Care Med 1999; 160:216-20.
18. 2α isoprostane in cystic fibrosis. Lipids 1999;34: 551-6.
19. 19 Loukides S, Horvath I, Wodehouse T, et al. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am J Respir Crit Care Med 1998;158:991-4.
20. 20 Kharitonov SA, Chung FK, Evans DJ, et al. The elevated level of exhaled nitric oxide in asthmatic patients is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med 1996;153:1773-80.
21. 2α. J Biol Chem 1995;270:9800-8.
22. 2 alpha in vitro and in vivo via the cyclooxygenases. J Pharmacol Exp Ther 1997;282: 1658-65.
23. 2α release from guine-pig lung in vitro. Eur J Pharmacol 1999;365:59-64.
24. 24 Grasemann H, Michler E, Wallot M, et al. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997;24:173-7.
25. 25 Paredi P, Montuschi P, Shaha PL, et al. Exhaled carbon monoxide is elevated in cystic fibrosis. A new test for disease monitoring? Eur Respir J 1998;12 (Suppl 28):235s.
26. 26 Ho LP, Innes JA, Greening AP. Nitrite levels in breath condensate of patients with cystic fibrosis is elevated in contrast to exhaled nitric oxide. Thorax 1998;53:680-4.
27. 27 Jones KL, Bryan TW, Jinkins PA, et al. Superoxide causes a reduction in nitric oxide gas and an increase in nitrate. Am J Respir Crit Care Med 1998;157:A132.
28. 28 Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998;102:1200-7.
29. 29 Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343: 133-5.
30. 30 Choi AM, Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 1996;15:9-19.